Agonistic Antibody Therapy in Cancer

Immunostimulatory antibody offers an attractive way of boosting anti-cancer responses and might be used to potentiate existing responses for cancer immunotherapy. As a leading service provider in the field of antibody therapy for years, Creative Biolabs can provide customers with professional agonistic antibody development service in a customer leading manner. With experienced scientists, our antibody discovery department can help you decide the most suitable method to promote the development of your projects.

Mechanisms of Action of Agonistic Antibody

The immune system is regulated by a highly complex balance of signals transmitted by stimulatory and inhibitory receptors, such as 4-1BB, OX40, GITR, CD270, CD27, TNFRSF25, and CD40. These receptors are widely expressed on both immune suppressive cells such as regulatory T cells (Tregs), effector immune cells and antigen-presenting cells (APCs). Agonistic antibodies are a new type of antibodies developed to target these receptors and activate the immune system by acting as an agonist. They are fundamentally different from a monoclonal antibody which blocks negative immune checkpoints such as anti-CTLA-4 or anti-PD-1. Among these costimulatory targets, tumor necrosis factor receptor (TNFR) superfamily which is expressed on a wide variety of immune and non-immune cells, such as dendritic cells (DC), B cells, and monocytes, have been treated as main targets of the agonistic antibody for cancer immunotherapy.

Fig.1 Potential mechanisms of action of agonistic CD40 mAb on various immune effectors. (Vonderheide, 2013)

Current Status of Agonistic Antibody in Cancer Therapy

During the past years, numerous members of the TNFR superfamily, such as CD137, CD40, IL-2, have been treated as targets of the agonistic antibody for cancer immunotherapy. For example, CD137, which is found on various hematopoietic cells, including primed T cells, natural killer (NK) cells, neutrophils, monocytes, dendritic cells, and mast cells, is shown to be an important costimulatory molecule for T-cell activation. Engagement of CD137 on T cells by natural ligand or agonistic antibody could enhance T-cell proliferation and provide protection to CD8 T cells from activation-induced cell death. Stimulation of CD137 could also lead to the activation of dendritic cells, NK cells, and macrophages in vitro. What’s more, agonistic CD40 mAb has been shown to activate APC and promote anti-tumor T cell responses and to foster cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity.

Creative Biolabs has been committed to delivering high-quality agonistic antibody development services in a variety of ways to efficiently accelerate your project's development. We offer one-stop services about the development of agonistic antibodies targeting numerous receptors or ligands. Please feel free to contact us for more details and our scientists will tailor the most reasonable scheme for your projects.

Reference

Vonderheide, R.H. and Glennie, M.J. Agonistic CD40 antibodies and cancer therapy. 2013.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: